Telemonitoring to Optimize Medication Titration for Heart Failure: a Feasibility Study

Inclusion Criteria: 1. Clinical symptoms of Dyspnoea (exertional or at rest) and 1 of the following signs: * Congestion on chest X-ray * Rales on chest auscultation * Clinically relevant oedema (e.g. ≥1+ on a 0 to 3+ scale) * Elevated jugular venous pressure. 2. NT-proBNP which is measured within the same hospitalization with level \>300ng/L or 600ng/L if ongoing atrial fibrillation/atrial flutter. 3. Left ventricular ejection fraction less than 40% by any form of imaging. Exclusion Criteria: 1. Documented history of HF with previous HF admission. 2. Current hospitalization for acute HF primarily triggered by pulmonary embolism, cerebrovascular accident, or acute MI. 3. Cardiac interventions (listed below) in past 30 days prior or planned during the study period. 1. Major cardiac surgery, or Tran Aortic Valve Implantation, or Percutaneous Coronary Intervention, or MitraClip 2. Current or expected heart transplant, LVAD, IABP, or patients with planned inotropic support in an outpatient setting. 4. Haemodynamically severe uncorrected primary cardiac valvular disease. 5. eGFR \<30 mL/min/1.73m2 as measured during index hospitalization (latest measurement before randomization) or patients requiring dialysis. 6. Documented allergy or intolerance to beta-blocker, renin-angiotensin-aldosterone system inhibitor, mineralocortical receptor antagonist, or angiotensin receptor/neprilysin inhibitor. 7. Pregnant or nursing women. 8. Psychiatric or severe neurological disorder, cirrhosis, or active malignancy leading to a life expectancy \< 6 months. 9. Non-ambulatory patients. 10. Patients who are unable to operate simple electronic devices; or unable to assess a mobile network service in the place of residence. 11. Patients who are unable to given written informed consent.